Home Newsfeeds Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

The Duckhorn Portfolio, Inc. Sees FY24 EPS $0.67-$0.69 Vs $0.68 Est.; Revenue $420M-$427M Vs $430.24M Est.

By Benzinga Newsdesk

December 6, 5:14 PM

Fiscal Year 2024 GuidanceThe Company is updating guidance to the following ranges below for Fiscal Year 2024 (excluding any impact from the pending acquisition of Sonoma-Cutrer Vineyards):(amounts in millions, except per

NAPA

Movers
News

Why Doximity Stock Took A Nosedive Today

By Ryan Gustafson

August 9, 2:37 PM

Doximity, Inc. (NYSE: DOCS) shares fell Wednesday after the company issued second-quarter and full-year 2023 revenue guidance below estimates.

DOCS

Payoneer Global Q2 EPS $0.01 Beats $(0.06) Estimate, Sales $148.19M Beat $131.48M Estimate

By Michael Horton

August 11, 4:32 PM

Payoneer Global (NASDAQ:PAYO) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.06) by 116.67 percent. This is a 101.33 percent increase over losses of $(0.75) per share from

PAYO